Products for the treatment of inflammatory bowel disease: A patent review (2013-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 6, 2015, Pages 629-642

  Di Stasi, Luiz C ^a   Costa, Celso Ara ^a   Witaicenis, Aline ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Colitis; Crohn's disease; Functional foods; Inflammatory bowel disease; Intestinal anti inflammatory compounds; MAb; Natural products; Prebiotic; Probiotic

Indexed keywords

ALGINIC ACID; ALPHA5 INTEGRIN; ALPHA5 INTEGRIN ANTAGONIST; ALPHA7 RECEPTOR BINDING CHOLINERGIC AGONIST; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL PRODUCT; CHOLINERGIC RECEPTOR STIMULATING AGENT; GUANYLATE CYCLASE C AGONIST; GUANYLATE CYCLASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HYALURONIC ACID; LACTOCEPIN; SECO A 2, 19 DINOR 1,25 DIHYDROXYVITAMIN D3; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; WS 727713;

BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; FUNCTIONAL FOOD; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PATENT; PHARMACEUTICAL CARE; REVIEW; SACCHAROMYCES CEREVISIAE; WHEAT GERM; ANIMAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG DESIGN; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG DESIGN; FUNCTIONAL FOOD; HUMANS; PATENTS AS TOPIC;

EID: 84930199714     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1041921     Document Type: Review

References (129)

1. Ghosh S, Pariente B, Mould DR, et al. New tools and approaches for improved management of inflammatory bowel diseases. J Crohns Colitis 2014;8(10):1246-53
2. Aloi M, Nuti F, Stronati L, et al. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol 2014;11(2):99-108
3. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474(7351):298-306
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411(6837):603-6
5. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013;5:237-47
6. Gisbert JP, Domenech E. Vedolizumab in the treatment of Crohn's disease. Gastroenterol Hepatol 2015. [Epub ahead of print]
7. Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011;60(12):1754-63
8. Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013;9(1):77-92
9. Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014;147(5):981-9
10. Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 2014;7:113-20
11. Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2014; Epub ahead of print
12. D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56(5):725-32
13. Forbes W, Borte E, Johnson L, et al. Formulations and uses of 2-hydroxy-5- phenylazobenzoic acid derivatives for the treatment of males. Salix Pharmaceuticals, Ltd. US8497256B2; 2013
14. Pravda J. Methods for treatment for ulcerative colitis in mammals. Therapeutic Research, LLC. USPTO8476233; 2013
15. Lichtenberger LM. Preparations of pharmaceuticals containing 5-Amino salicylic acid and phospholipids for treatment of inflammatory bowel disease. Board Of Regents Of The University Of Texas System. JPO2014015478; 2014
16. Wolfe HRE. Therapeutic peptides. Combimab, Inc. USPTO8748575; 2014
17. Shailubhai K. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders. Synergy Pharmaceuticals Inc. USPTO8569246; 2013
18. Pitari GM. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther 2013;7:351-60
19. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
20. Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9(4):403-10
21. Guarino A, Cohen MB, Giannella RA. Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heatstable enterotoxin. Pediatr Res 1987;21(6):551-5
22. Waldman SA, O'Hanley P, Falkow S, et al. A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli. J Infect Dis 1984;149(1):83-9
23. Han X, Mann E, Gilbert S, et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One 2011;6(1):e16139
24. Lin JE, Snook AE, Li P, et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One 2012;7(2):e31686
25. Barbera Betancourt A, del Carmen Dominguez Horta M, Lorenzo Perez N, et al. Method of inducing T cell apoptosis by administering Altered Peptide Ligand. Cuba; Centro de Ingenieria Genetica y Biotecnologia. USPTO8410057; 2013
26. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med (Berl) 2001;79(10):552-65
27. Paterson B, Tamiz A, Pandey N, et al. Use of tight junction antagonists to treat inflammatory bowel disease. Alba Therapeutics Corp. USPTO8796203; 2014
28. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci 2012;1258:25-33
29. Vanuytsel T, Vermeire S, Cleynen I. The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. Tissue Barriers 2013;1(5):e27321
30. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 genedeficient mouse. Gut 2009;58(1):41-8
31. Wu TC. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease. Holy Stone Healthcare Co., Ltd. USPTO8575130; 2013
32. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an informationrich system. Eur J Cell Biol 2006;85(8):699-715
33. Xu YZ, Yuan S, Wone D, et al. Pyridinone antagonists of alpha-4 integrins. Elan Pharmaceuticals, Inc. USPTO8367836; 2013
34. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des 2002;8(14):1229-53
35. Greene MI, Hancock MW, Katsumata M, et al. Therapy of autoimmune colitis using a TIP60 inhibitor. The Trustees Of The University Of Pennsylvania, The Children's Hospital of Philadelphia. USPTO8497285; 2013
36. Xiao Y, Nagai Y, Deng G, et al. Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60. Cell Rep 2014;7(5):1471-80
37. DeLuca HF, Clagett-Dame M, Plum LA, et al. A-ring modified 19-nor-vitamin D analogs and their uses. Wisconsin Alumni Research Foundation. USPTO8785422; 2014
38. Ganapathy V, Prasad PD, Martindale RG, et al. Prodrugs of shortchain fatty acids and treatment methods. Georgia Health Sciences University Research Institute, Inc. USPTO8518989; 2013
39. Haller D, Hormannsperger G. Lactocepins for use in the treatment of IP-10-mediated inflammatory diseases. Technische Universitat Munchen. WO0209411; 2013
40. Tracey KJ, Wang H. Inhibition of inflammation using a7 receptor-binding cholinergic agonist. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014
41. Yamamuro N, Nakamaru K, Yasue T. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient. North Shore-Long Island Jewish Research Inst. JPO2014055178; 2014
42. Takanao O; Hirotsugu c/o Astellas Pharma Inc; UEDA, Keiko c/o Astellas Pharma Inc. et al. Compound WS727713. Telsar Pharma Inc. JPO2014040456; 2014
43. Yamamoto A, Nasu R, Ito Y. Composition for preventing and/or treating colonic inflammatory disease. Kaigen Pharma Co. Ltd. JPO2014009179; 2014
44. Tsutsumi Y, Yoshioka Y, Yoshikawa T, et al. Preventive or therapeutic agent for inflammatory bowel disease. Vitamin C60 Bioresearch Kk. Osaka Univ. JPO2013087108; 2013
45. Sheridan H, Frankish N. Indene derivatives for use in the treatment of inflammatory bowel disease. Venantius Ltd. EP2734496A1; 2013
46. Eussen SR, Verhagen H, Klungel OH, et al. Functional foods and dietary supplements: products at the interface between pharma and nutrition. Eur J Pharmacol 2011;668(Suppl 1):S2-9
47. Roberfroid M. Functional food concept and its application to prebiotics. Dig Liver Dis 2002;34(Suppl 2):S105-10
48. Diplock AT, Ashwell M, Bomet F, et al. Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 1999;81(Suppl 1):S1-27
49. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009;15(3):454-62
50. Toumi R, Soufli I, Rafa H, et al. Probiotic bacteria lactobacillus and bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice. Int J Immunopathol Pharmacol 2014;27(4):615-27
51. Elian SD, Souza EL, Vieira AT, et al. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. Benef Microbes 2015;6(3):277-86
52. Shadnoush M, Shaker Hosseini R, Mehrabi Y, et al. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. Iran J Pharm Res 2013;12(4):929-36
53. Lorea Baroja M, Kirjavainen PV, Hekmat S, et al. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007;149(3):470-9
54. Viladomiu M, Hontecillas R, Yuan L, et al. Nutritional protective mechanisms against gut inflammation. J Nutr Biochem 2013;24(6):929-39
55. Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol 2014;20(33):11505-24
56. Borchers AT, Selmi C, Meyers FJ, et al. Probiotics and immunity. J Gastroenterol 2009;44(1):26-46
57. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125(6):1401-12
58. Roberfroid MB. Fructo-oligosaccharide malabsorption: benefit for gastrointestinal functions. Curr Opin Gastroenterol 2000;16(2):173-7
59. Tojo R, Suarez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014;20(41):15163-76
60. Chen Y, Zhang H, Wang Y, et al. Acetylation and carboxymethylation of the polysaccharide from Ganoderma atrum and their antioxidant and immunomodulating activities. Food Chem 2014;156:279-88
61. Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc 2014;73(4):490-7
62. Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013;2013:435268
63. Yu CG, Huang Q. Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. J Dig Dis 2013;14(10):513-17
64. Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol 2013;48(3):315-21
65. Wu GD, Bushmanc FD, Lewis JD. Diet, the human gut microbiota, and IBD. Anaerobe 2013;24:117-20
66. Roy CC, Kien CL, Bouthillier L, et al. Short-chain fatty acids: ready for prime time? Nutr Clin Pract 2006;21(4):351-66
67. Hu GX, Chen GR, Xu H, et al. Activation of the AMP activated protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect of a high fiber diet on the metabolic syndrome. Med Hypotheses 2010;74(1):123-6
68. den Besten G, van Eunen K, Groen AK, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013;54(9):2325-40
69. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011;13(5):517-26
70. Blouin JM, Penot G, Collinet M, et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer 2011;128(11):2591-601
71. Tang Y, Chen Y, Jiang H, et al. G-protein-coupled receptor for shortchain fatty acids suppresses colon cancer. Int J Cancer 2011;128(4):847-56
72. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008;27(2):104-19
73. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990;70(2):567-90
74. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83(2):424-9
75. Vinolo MA, Rodrigues HG, Hatanaka E, et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 2011;22(9):849-55
76. Soldavini J, Kaunitz JD. Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig Dis Sci 2013;58(10):2756-66
77. Bringiotti R, Ierardi E, Lovero R, et al. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014;5(4):550-9
78. Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl Microbiol 2004;54:261-89
79. Raso E, Lapis K. Use of fermented wheat germ in the treatment of inflammatory bowel disease. 3 CH Ltd., Raso, Erzsebet; Lapis, Karoly. WO2012159988; 2014
80. Demidov LV, Manziuk LV, Kharkevitch GY, et al. Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of highrisk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. Cancer Biother Radiopharm 2008;23(4):477-82
81. Balint G, Apathy A, Gaal M, et al. Effect of Avemar-A fermented wheat germ extract-on rheumatoid arthritis. Preliminary data. Clin Exp Rheumatol 2006;24(3):325-8
82. Farkas E. Fermented wheat germ extract in the supportive therapy of colorectal cancer. Orv Hetil 2005;146(37):1925-31
83. Jakab F, Shoenfeld Y, Balogh A, et al. A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 2003;89(3):465-9
84. Jakab F, Mayer A, Hoffmann A, et al. First clinical data of a natural immunomodulator in colorectal cancer. Hepatogastroenterology 2000;47(32):393-5
85. Sukkar S, Cella F, Rovera G, et al. A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar). Mediterr J Nutr Metab 2008;1(1):37-42
86. MacSharry J, O'Mahony L, O'Sullivan D, et al. Probiotic bifidobacterium strains. Alimentary Heath Ltd. USPTO8557233; 2013
87. Mojca Lunder L, Ravnikar M, Strukelj B, et al. Modified food grade microorganism for treatment of inflammatory bowel disease. University of Ljubljana; Institute Jozef Stefan; Labena d.o.o. US8754198B2; 2014
88. Veiga P, Chambaud I, Khlebnikov A, et al. Method for reducing gastrointestinal inflammation using Bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria. Compagnie Gervais Danone; President and Fellows of Harvard College. USPTO8685388; 2014
89. Guyonnet D, Schlumberger A, Mhamdi L, et al. Fermented milk containing Bifidobacterium lactis DN-173 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009;102(11):1654-62
90. Veiga P, Gallini CA, Beal C, et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci USA 2010;107(42):18132-7
91. Israelsen H. Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effector. Nordisk Rebalance As. JPO2013144712; 2013
92. Krag A, Munkholm P, Israelsen H, et al. Profermin is efficacious in patients with active ulcerative colitis-A randomized controlled trial. Inflamm Bowel Dis 2013;19(12):2584-92
93. Krag A, Israelsen H, von Ryberg B, et al. Safety and efficacy of Profermin(R) to induce remission in ulcerative colitis. World J Gastroenterol 2012;18(15):1773-80
94. Daisuke M, Asama T, Motoki H, et al. New lactic acid bacteria having promotion activity for IgA production and use of the same. Yamada Bee Co., Inc. JPO2014073130; 2013
95. Saburo M, Tomohiro O, Hiroyuki S, et al. Inflammatory bowel disease inhibitor, and food and drink. Tottori Univaon Chemical Kkota Suten: Kktottori Institute of Industrial Technology. JPO2013180958; 2013
96. Wakuda T, Azuma K, Saimoto H, et al. Protective effects of galacturonic acid-rich vinegar brewed from Japanese pear in a dextran sodium sulfate-induced acute colitis model. J Funct Foods 2013;5(1):516-23
97. Raine T. Vedolizumab for inflammatory bowel disease: changing the game, or more of the same? United European Gastroenterol J 2014;2(5):333-44
98. Zampeli E, Gizis M, Siakavellas SI, et al. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014;5(3):293-303
99. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61(6):918-32
100. Garnock-Jones KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. BioDrugs 2015;29(1):57-67
101. Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7(8):636-43
102. McKenzie ANJ, Neill D. Antibodies against IL-17BR. Medical Research Council. USPTO8586037; 2013
103. Camelo A, Barlow JL, Drynan LF, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol 2012;47(11):1198-211
104. Saadoun D, Terrier B, Cacoub P. Interleukin-25: key regulator of inflammatory and autoimmune diseases. Curr Pharm Des 2011;17(34):3781-5
105. Monteleone G, Pallone F, Macdonald TT. Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev 2010;21(6):471-5
106. Shibuya A, Oda C, Iino S, et al. Medicine comprising active modulator of CD300a-expressing cell associated with inflammatory bowel disease, CD300aa gene knock-out mouse, and use of active modulator of CD300a-expressing cell. University of Tsukuba. JPO2014094898; 2014
107. DeBell KE, Simhadri VR, Mariano JL, et al. Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a. BMC Immunol 2012;13:23
108. Tanaka T, Tahara-Hanaoka S, Nabekura T, et al. PPARbeta/delta activation of CD300a controls intestinal immunity. Sci Rep 2014;4:5412
109. Pickford LB, Bebbington CR, Yarranton GT, et al. Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist. Medarex, L.L.C. USPTO8828393; 2014
110. Monteleone G, Pender SL, Alstead E, et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001;48(3):425-9
111. Fais S, Capobianchi MR, Silvestri M, et al. Interferon expression in Crohn's disease patients: increased interferongamma and -Alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994;14(5):235-8
112. Kole A, He J, Rivollier A, et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cellmediated colitis. J Immunol 2013;191(5):2771-9
113. Cho H, Kelsall BL. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev 2014;260(1):145-67
114. Monteleone G. Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field. Nogra Pharma Ltd. USPTO8648186; 2014
115. Zorzi F, Angelucci E, Sedda S, et al. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig Liver Dis 2013;45(7):552-5
116. Monteleone G, Caruso R, Pallone F. Role of Smad7 in inflammatory bowel diseases. World J Gastroenterol 2012;18(40):5664-8
117. Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012;20(4):870-6
118. Frey MR. Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis. Children's Hospital Los Angeles. EP2744512A1; 2013
119. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008;65(10):1566-84
120. Bernard JK, McCann SP, Bhardwaj V, et al. Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo. J Biol Chem 2012;287(47):39850-8
121. McElroy SJ, Castle SL, Bernard JK, et al. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis. Am J Pathol 2014;184(10):2768-78
122. Weinstock JV, Elliot DE. Use of parasitic biological agents for prevention and control of autoimmune diseases. University of Iowa Research Foundation. JPO2014129390; 2014
123. Chen NJ, Huang MW, Hsieh SL. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activationinduced cytokine. J Immunol 2001;166(1):270-6
124. Heylen M, Ruyssers NE, Gielis EM, et al. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 2014;143(2):153-67
125. Grzych JM, Pearce E, Cheever A, et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol 1991;146(4):1322-7
126. Oswald IP, Caspar P, Jankovic D, et al. IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 1994;153(4):1707-13
127. Zhang C, Li Y, Xu Y, et al. Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases. Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Chenggang Zhang, Junhuai LI, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li, Institute Of Radiation Medicine, Academy Of Military Medical Sciences, People's Liberation Army Of China. EP2730287A1; 2013
128. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167(3):1609-16
129. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113(9):1296-306